Smad7 knockdown activates protein kinase RNA-associated eIF2α pathway leading to colon cancer cell death
Veronica De Simone1, Gerolamo Bevivino1, Silvia Sedda1
1Department of Systems Medicine, University of 'Tor Vergata', Rome, Italy.
Abstract:
Upregulation of Smad7, an inhibitor of transforming growth factor-β1 (TGF-β1), occurs in sporadic colorectal cancer (CRC) and knockdown of Smad7 inhibits CRC cell growth, a phenomenon that associates with decreased expression of cell division cycle 25 homolog A and arrest of cells in the S phase of the cell cycle. These findings occur in CRC cells unresponsive to TGF-β1, thus suggesting the existence of a Smad7-mediated TGF-β1-independent mechanism that controls CRC cell behavior. Here we show that Smad7 inhibition with a specific Smad7 antisense oligonucleotide upregulates eukaryotic translation initiation factor 2α (eIF2α) phosphorylation, a transcription factor involved in the regulation of cell cycle arrest and induction of cell death, and induces activating transcription factor 4 (ATF4) and CCAAT/enhancer binding protein homology protein (CHOP), two downstream targets of eIF2α. Among the upstream kinases that control eIF2α phosphorylation, the serine-threonine protein kinase RNA (PKR), but not general control non-derepressible 2 (GCN2) and protein kinase RNA-like endoplasmic reticulum kinase (PERK), is activated by Smad7 knockdown. PKR silencing abolishes Smad7 antisense-induced eIF2α phosphorylation and ATF4/CHOP induction, thereby preventing Smad7 antisense-driven cell death. Smad7 inhibition diminishes interaction of PKR with protein kinase inhibitor p58 (p58IPK), a cellular inhibitor of PKR, but does not change the expression and/or activity of other factors involved in the control of PKR activation. These findings delineate a novel mechanism by which Smad7 knockdown promotes CRC cell death.
Insights
Smad7 inhibition in colorectal cancer (CRC) cells activates PKR, leading to eIF2α phosphorylation and cell death. This reveals a novel TGF-β1-independent pathway controlling CRC progression.
Area of Science:
- Oncology
- Molecular Biology
- Cell Biology
Background:
- Smad7, a transforming growth factor-β1 (TGF-β1) inhibitor, is upregulated in sporadic colorectal cancer (CRC).
- Smad7 knockdown inhibits CRC cell growth, suggesting a TGF-β1-independent mechanism.
- This mechanism involves cell division cycle 25 homolog A downregulation and S-phase cell cycle arrest.
Purpose of the Study:
- To elucidate the TGF-β1-independent mechanism by which Smad7 knockdown affects CRC cell behavior.
- To investigate the role of eukaryotic translation initiation factor 2α (eIF2α) phosphorylation in Smad7-mediated CRC cell death.
- To identify the upstream kinase responsible for eIF2α phosphorylation upon Smad7 inhibition.
Main Methods:
- Smad7 was inhibited using a specific Smad7 antisense oligonucleotide.
- eIF2α phosphorylation, ATF4, and CHOP induction were assessed.
- The involvement of protein kinase RNA (PKR), GCN2, and PERK in eIF2α phosphorylation was investigated.
- PKR silencing and interaction studies with p58IPK were performed.
Main Results:
- Smad7 inhibition upregulated eIF2α phosphorylation, inducing ATF4 and CHOP.
- PKR, but not GCN2 or PERK, was activated by Smad7 knockdown.
- PKR silencing prevented Smad7 antisense-induced cell death.
- Smad7 inhibition reduced the interaction between PKR and its inhibitor p58IPK.
Conclusions:
- Smad7 knockdown promotes CRC cell death through a novel TGF-β1-independent pathway.
- This pathway involves the activation of PKR, leading to eIF2α phosphorylation and subsequent induction of apoptosis.
- Targeting Smad7 may represent a potential therapeutic strategy for colorectal cancer.
More Related Videos
Related Concept Videos
MAPK Signaling Cascades
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway
Abnormal Proliferation
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
The Intrinsic Apoptotic Pathway


